Key result
At pharmacological concentrations, melatonin significantly decreased the conversion of arachidonic acid to prostaglandin F2 and thromboxane B2, indicating inhibition of human platelet cyclooxygenase.
At pharmacological concentrations, melatonin inhibits human platelet cyclooxygenase, reducing the formation of thromboxane B2 and other derivatives.
Answers are grounded in this paper and cite their sources.
Melatonin may inhibit platelet COX at high doses; animal data leave open any human antithrombotic role.
The effect of melatonin on thrombin-induced [3H]-arachidonic acid (AA) metabolism to cyclooxygenase derivatives was determined in platelets obtained from normal volunteers at 0830 and 2030 h. Percent conversion of radioactive AA was generally greater at 2030 h than at 0830 h for every cyclooxygenase derivative analyzed. Micromolar or greater concentrations of melatonin decreased significantly the conversion of [3H]-AA to prostaglandin (PG) F2 and thromboxane (Tx) B2, and inhibited slightly the conversion to PGE2 and PGD2. After preincubation of platelets with 1 mM imidazole, the melatonin inhibitory effect was significant for PGF2 only. Melatonin (10(-6) M) showed a significant inhibitory influence on platelet ATP release induced by phorbol-12 myristate-13 acetate (PMA) at 2030 h, an effect inhibited by 1 mM aspirin. These results indicate that at pharmacological concentrations melatonin inhibits human platelet cyclooxygenase.
No takes yet. Share an insight, caveat, or question.
Martinuzzo et al. (1991) studied this question. Melatonin was evaluated on Conversion of [3H]-arachidonic acid to cyclooxygenase derivatives. At pharmacological concentrations, melatonin significantly decreased the conversion of arachidonic acid to prostaglandin F2 and thromboxane B2, indicating inhibition of human platelet cyclooxygenase.
Synapse has enriched 10 related papers. Consider them for comparative context: